Effect of anaemia on mortality, cardiovascular hospitalizations and end‐stage renal disease among patients with chronic kidney disease

Abstract

Anaemia is a predictor of excess mortality, excess cardiovascular hospitalizations and excess end-stage renal disease even when the progression of CKD is considered by controlling for time-varying eGFR values.

Profile of Anemia in Chronic Kidney Disease Patients at a Rural Tertiary Care Centre: A Prospective Observational Study

“…It is also associated with progression of renal disease and increased mortality. 3,10 Increased healthcare costs and woersened quality of life are other issues of concern in CKD patients with Anemia. 3 Therefore, evaluation of prevalence and etiological profile of Anemia in Chronic Kidney Disease patients at the regional level is important from the point of view of optimum allocation of health care resources, especially in resource limited settings in developing countries like India.…”

Utilização de eritropoetina por pacientes incidentes em hemodiálise no Sistema Único de Saúde, Brasil, 2002-2003

“…Esse quadro pode confirmar a contribuição do tratamento da anemia para a diminuição da mortalidade nos pacientes em hemodiáli-se, conforme relatado na literatura 4,9,12,13 .…”

“…Também pode ocasionar aumento da sobrecarga cardíaca, levando à hipertrofia ventricular esquerda e à miocardiopatia 6,8 . Assim, a anemia em pacientes com doença renal crônica está associada ao aumento da morbidade e da mortalidade, à progressão mais rápida para doença renal em está-gio final e à piora de sua qualidade de vida 6,12,13 .…”

Clinical and Economic Outcomes in Medicare Beneficiaries with Stage 3 or Stage 4 Chronic Kidney Disease and Anemia: The Role of Intravenous Iron Therapy

“…2 Anemia is a common occurrence in CKD patients and is associated with increased morbidity and mortality. 4 In a sample of patients with incident CKD, Thorp et 4 Anemia is defined by a decrease in hematocrit or Hb. It develops as kidney function deteriorates primarily due to the decreased production of erythropoietin (EPO) and impairs the body's ability to provide an adequate oxygen supply to organs.…”

“…In a sample of patients with incident CKD, Thorp et al (2009) [IV]) in CKD patients with anemia (defined as hematocrit less than 33% in women of childbearing age or less than 37% in men and postmenopausal women) in whom therapy with an erythropoiesisstimulating agent (ESA) does not raise the hematocrit above the threshold levels because iron levels are too low. Iron deficiency is defined in the NIDDK guidelines as a ferritin score less than 100 micrograms (mcg) per liter and a transferrin saturation (TSAT) score less than 20%.…”